Mind Medicine (NEO: MMED) has seen further management departures, following the departure of its CEO this past summer. Classified as “transitions,” the firm has lost both its Chief Technology Officer, as well as its Chief Scientific Officer.
The first executive to depart, Bradford Cross, is said to have “transitioned from his role,” although the company doesn’t state exactly what Cross is transitioning to – however Mind Medicine has been removed entirely from his LinkedIn page, while the company has removed any information on him from their website, indicating he has “transitioned” out of the company. Cross previously was lead on the firms digital therapeutics platform, which will now be lead by Chief Medical officer Dr Daniel Karlin.
Don Gehlert is the second departure from the company, whom will be leaving his role as Chief Scientific Officer. Instead, he will be servicing as a Senior Scientific Advisor, and “continue to be an integral part” of Mind Medicine. He meanwhile lists himself as a consultant for the firm on LinkedIn.
Mind Medicine last traded at $2.18 on the Neo.
Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.